Myfortic (Mycophenolic Acid)

Mycophenolic Acid blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for making guanosine nucleotides. Lymphocytes rely on this pathway for proliferation, so inhibition reduces T‑ and B‑cell expansion and dampens the immune response that can attack a transplanted organ.

The dosage of Myfortic is individualized by the treating physician based on the type of transplant, patient weight, renal function, and concurrent immunosuppressants. Only a qualified prescriber can determine the appropriate regimen for each patient.

Myfortic should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians typically assess the transplant‑related necessity against possible developmental effects and advise patients accordingly.

To place an order, submit an enquiry on the Myfortic product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to Myfortic is azathioprine, another immunosuppressant that interferes with DNA synthesis. Myfortic generally offers more selective inhibition of lymphocyte proliferation with a different side‑effect profile, while azathioprine may have broader bone‑marrow suppression. Choice depends on patient tolerance, organ type, and physician preference.

Myfortic should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablet appears discoloured.

Myfortic is taken orally, usually twice daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

The most critical risks include severe infections, marked leukopenia or anemia, and a rare but possible increased incidence of certain cancers. Patients should promptly report fever, persistent cough, unusual bruising, or any signs of infection to their healthcare provider.

Myfortic is contraindicated in individuals with known hypersensitivity to mycophenolic acid or any of its excipients. It should also be avoided in patients with uncontrolled severe infections or those receiving live vaccines without appropriate medical supervision.